A Phase 2 interventional study of BTX 1503 and Vehicle in Acne Vulgaris, sponsored by Botanix Pharmaceuticals. Completed at 36 sites in 2 countries. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-04-18.
Sponsored by Botanix Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 95th largest by enrollment of the 353 interventional ones that give a count, is one of 20 that started in 2018, is one of 65 in phase 2, and was the 253rd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 20 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 368 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 322 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
Botanix Pharmaceuticals is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Botanix Pharmaceuticals has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
This will be a multi-center, randomized, double-blinded, vehicle-controlled, parallel group, dose-finding study in pediatrics, adolescents and adults (aged 12 to 40 years). The objective of this study is to assess the safety and efficacy of various doses of BTX 1503 in subjects with moderate to severe acne vulgaris of the face.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has acne vulgaris of the face defined as:
Sexually active women must agree to use the following throughout the study and for 30 days after last study drug application:
a. One of these highly effective contraception methods i. Intrauterine device (IUD); hormonal (injections, implants, transdermal patch, vaginal ring; tubal ligation; partner vasectomy, OR b. Oral contraceptives WITH a barrier method (listed below), OR c. Two barrier forms of contraception (listed below) i. Male or female condom; diaphragm; cervical cap.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BTX 1503 5% CBD (w/w) solution twice daily
Drug: BTX 1503
BTX 1503 5% CBD (w/w) solution once daily
Drug: BTX 1503
BTX 1503 2.5% CBD (w/w) solution once daily
Drug: BTX 1503
Vehicle twice daily
Drug: Vehicle
Vehicle once daily
Drug: Vehicle
BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
Also known as: BTX1503
Placebo
Safety as Measured by Reported Adverse Events
Summary of Treatment-Emergent Adverse Events by MedDra Preferred Term that Occurred with a Frequency \> 2% in any Treatment Group (Safety Population)
Time frame: Day 84
Absolute Change From Baseline in Inflammatory Lesion Counts
Summary of Absolute Change from Baseline in Inflammatory Count at Day 84 (Intent-to-Treat Population)
Time frame: Day 84
| Milestone | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) |
|---|---|---|---|---|
| Started | 92 | 92 | 92 | 92 |
| Completed | 69 | 77 | 70 | 81 |
| Not completed | 23 | 15 | 22 | 11 |
Summary of Treatment-Emergent Adverse Events by MedDra Preferred Term that Occurred with a Frequency \> 2% in any Treatment Group (Safety Population)
| TEAEs | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) |
|---|---|---|---|---|
| Upper Respiratory tract infection | 2 | 4 | 5 | 5 |
| Viral upper respiratory tract infection | 3 | 2 | 3 | 4 |
| Headache | 1 | 1 | 2 | 0 |
| Acne | 2 | 0 | 2 | 0 |
| Cough | 1 | 0 | 2 | 0 |
| Oropharyngeal pain | 0 | 2 | 0 | 1 |
Summary of Absolute Change from Baseline in Inflammatory Count at Day 84 (Intent-to-Treat Population)
| Lesions | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) |
|---|---|---|---|---|
| Absolute Change From Baseline in Inflammatory Lesion Counts | -8.5 ± 12.57 | -12 ± 12.58 | -11.7 ± 12.57 | -11.3 ± 12.57 |
Collected over Approximately 3 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BTX 1503 5% BID | 0/92 (0%) | 0/92 (0%) | 9/92 (9.8%) |
| BTX 1503 5% QD | 0/91 (0%) | 0/91 (0%) | 9/91 (9.9%) |
| BTX 1503 2.5% QD | 0/91 (0%) | 0/91 (0%) | 14/91 (15.4%) |
| Vehicle Combined (BID or QID) | 0/91 (0%) | 0/91 (0%) | 10/91 (11%) |
| Event | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) |
|---|---|---|---|---|
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 2/92 | 4/91 | 5/91 | 5/91 |
| Viral upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 3/92 | 2/91 | 3/91 | 4/91 |
| HeadacheNervous system disorders | 1/92 | 1/91 | 2/91 | 0/91 |
| AcneSkin and subcutaneous tissue disorders | 2/92 | 0/91 | 2/91 | 0/91 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/92 | 0/91 | 2/91 | 0/91 |
| Oorpharyngeal PainGastrointestinal disorders | 0/92 | 2/91 | 0/91 | 1/91 |
| Age, Continuous(years) | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) | Total |
|---|---|---|---|---|---|
| Mean | 19.5 ± 6.65 | 19.7 ± 5.99 | 19.4 ± 5.98 | 20.5 ± 6.14 | 20.0 ± 6.17 |
| Sex: Female, Male(Participants) | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) | Total |
|---|---|---|---|---|---|
| Female | 56 | 60 | 58 | 55 | 229 |
| Male | 36 | 32 | 34 | 37 | 139 |
| Ethnicity (NIH/OMB)(Participants) | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 26 | 21 | 23 | 23 | 93 |
| Not Hispanic or Latino | 66 | 71 | 69 | 69 | 275 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 5 | 5 | 5 | 7 | 22 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 1 | 1 | 5 |
| Black or African American | 12 | 5 | 5 | 6 | 28 |
| White | 67 | 75 | 73 | 72 | 287 |
| More than one race | 5 | 6 | 8 | 6 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Inflammatory Lesion Count(Lesions) | BTX 1503 5% BID | BTX 1503 5% QD | BTX 1503 2.5% QD | Vehicle Combined (BID or QID) | Total |
|---|---|---|---|---|---|
| Mean | 29.3 ± 8.52 | 28.5 ± 8.95 | 29.6 ± 8.00 | 29.1 ± 8.25 | 29.1 ± 8.37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Aug 2019, 13 months.
Results were first posted in Apr 2022, 2 years 8 months after primary completion.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 13 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Botanix Pharmaceuticals